|
|
Jean-Pierre Kraehenbuhl obtained a MD degree at the University of Lausanne in 1967. He did an internship in Medicine at the Hospital of La Chaux de Fonds. In 1970, he joined as a Post-postdoctoral fellow the laboratory of Dr. G. Palade at Rockefeller University in New York. In 1973 he was appointed Assistant Professor at Yale University School of Medicine. In 1975, he returned to the Institut of Immunobiology (formerly Biochemistry) of the University of Lausanne as an Assistant Professor, and in 1979 he was appointed Associate Professor. From 1977 to 1986 he was the chairman of the 3e cycle of Biological Sciences. In 1979, he received the Cloëtta Prize. In 1984 he was appointed Senior staff member of the Swiss Institute of Experimental Cancer Research and Full Professor at the Faculty of Medicine, University of Lausanne. In 1989, he founded OraVax together with Prof. Marian Neutra from Harvard Medical School, a start up company which became Acambis, Inc and which is now part of Sanofi Pasteur In 1992, he become a member of the European Molecular Bioogy Organization (EMBO). In 2002, he was the executive Vice President of EuroVacc Foundation, a European consortium for the development of a vaccine against AIDS HIV.. In 2003, he retired and in 2006 he created the Health Sciences eTraining (HSeT) Foundation. His research activities focused on epithelial membrane trafficking, mucosal immunity, and mucosal vaccine design. He was funded by the Swiss National Science Foundation since 1975, the Swiss League against Cancer since 1983. |
